Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Crinetics Pharmaceuticals Inc CRNX.OQ reported a quarterly adjusted loss of $1.23​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -94 cents. The mean expectation of fourteen analysts for the quarter was for a loss of $1.10 per share. Wall Street expected results to range from $-1.22 to -94 cents per share.

• Revenue rose 158.4% to $1.03 million from a year ago; analysts expected $129.17 thousand.

• Crinetics Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.23​.

• The company reported a quarterly loss of $115.64 million.

• Crinetics Pharmaceuticals Inc shares had fallen by 0.8% this quarter and lost 44.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.3% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Crinetics Pharmaceuticals Inc is $72.00, about 61.3% above its last closing price of $27.88

This summary was machine generated from LSEG data August 8 at 03:07 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)